TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Of Ergocalciferol In Adults According To BMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Study subjects have to be between the ages of 18 to 65 with a serum 25OHD level less than 20 ng/ml.~Exclusion Criteria:~* Participants will be excluded if they have any of the following:~  1. Due to the inaccuracies of BMI in patients with increased muscle mass, in group with a BMI 25-35: men with a waist circumference \< 90 cm ; women \< 80 cm~ 2. Chronic liver disease defined by any clinical or a history of serum AST or ALT \> 2 times ULN~ 3. Kidney disease defined as a GFR \<60 ml/min~ 4. Sarcoidosis~ 5. Any known malignancy~ 6. Known malabsorption disorder to include inflammatory bowel disease, celiac disease, cystic fibrosis, history of gastric bypass~ 7. Primary hyperparathyroidism or hypercalcemia,~ 8. Patients that are pregnant or considering pregnancy.~ 9. Patients taking certain medications such as glucocorticoids, anti-seizure medications such has phenobarbital or phenytoin or patients taking antiviral medications for HIV as these are known to cause vitamin D deficiency~ 10. Individuals excluded from having a DXA scan~Study participants will be excluded from having a DXA scan if any of the following:~1. Any amputation of a extremity including toes~2. If they have a pacemaker, automatic defibrillator, coronary stents or metal suture material in the heart~3. If they have artificial joints, pins, plate or any other type of metal objects~4. If they have received contrast material such as barium in the past 7 days~5. If they have had a nuclear medicine study in the past 3 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- BMI <25 (Type: EXPERIMENTAL): Normal BMI
- BMI 25-35 (Type: EXPERIMENTAL): Overweight and obese by BMI
- BMI >35 (Type: EXPERIMENTAL): Obese by BMI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Effect of Intranasal Calcitonin on Patients With Fractured Ribs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 or more.~* Accidental rib fracture (one or more) visible on a lung\\thorax radiography, or on a CT Scan of the thorax, as determined by the emergency physician or the radiologist.~* The rib fracture is the main cause of pain.~* The patient says yes to the question do you wish something for your pain (the result of the quantitative assessment of the pain in not taken into consideration) or the patient has already received an analgesic before the initial assessment by the emergency physician.~* The patient is seen no more than 48 hours after the accident.~Exclusion Criteria:~* The patient is already receiving SC.~* Allergy or intolerance to SC, oxycodone chlorhydrate or acetaminophen~* Active neoplasia history for at least 5 years~* Toxicomania history as revealed by case history~* Osteoporosis linked to hyperparathyroidism~* Patient already using opiate analgesics or other analgesics on a regular basis (excluding aspirin at doses of 325 mg or less, as a prophylactic for cardiovascular diseases and under stable posology for at least 15 days)~* Steroid use within the past month~* Pregnancy, breast feeding~* Non-availability of patient for telephone follow-ups or follow-up appointments.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of New Computerized Labor Monitoring System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Laboring women referred to the Maternity Center in active labor (3cm dilatation and contractions).~* Gestational age 37-42 weeks. (GA)~* Single fetus~* Subjects who understood, agreed and signed the informed consent form~Exclusion Criteria:~* Women with abnormal placentation (placenta previa)~* Women with coagulation abnormalities.~* Abnormal fetal presentation (breech presentation)~* Maternal History of HIV and/or blood transmitted hepatitis and/or active genital Herpes.~* Preterm premature rupture of membranes.~* Need for immediate delivery (cord prolapsed or suspected placental abruption

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): Women in active labor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed the RA0083 \[NCT01463059\] study (Week 12 Visit)~* Must have maintained their stable dose (and route) of methotrexate (MTX) between 6 to 16 mg/week in Japan or 7.5 to 20 mg/week in Korea and Taiwan in RA0083 \[NCT01463059\], and plan to maintain this same dose and route of administration for at least 12 weeks~* Female subjects must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing 2 acceptable methods of contraception~Exclusion Criteria:~* Have an ongoing SAE from the RA0083 \[NCT01463059\] study~* Female subjects who are breast-feeding, pregnant, or plan to become pregnant during the study or within 24 weeks~* Have evidence of active or latent tuberculosis (TB)~* Subject is receiving any biologic response modifier or synthetic disease-modifying antirheumatic drug (DMARD) other than MTX~* Subject has planned surgery during the first 12 weeks of the study~* Subjects who tested positive for hepatitis B core antibody (HBcAb) and/or hepatitis B surface antibody (HBsAb) at Screening in RA0083 \[NCT01463059\] and who subsequently test positive for hepatitis B virus deoxyribonucleic acid (HBV DNA) at Week 12 of RA0083 \[NCT01463059\]

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDP6038 (olokizumab) (Type: EXPERIMENTAL): CDP6038 (olokizumab) 120 mg: subcutaneous injections at q2w (every two weeks). RA0089 is a single arm study, however, analysis will be presented according to the original treatment arms of the parent study NCT01463059 (RA0083).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Immune Globulin (IVIG) Treatment Protocol in Kidney Transplant Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 12 years of age or older~* diagnosed with end stage renal disease~* currently receiving either hemodialysis or peritoneal dialysis~* active on the kidney or kidney/pancreas transplant list~* medical clearance of the kidney donor if live related transplant~* elevated panel reactive antibody (PRA) greater that 30% for 3 consecutive monthly tests and one positive crossmatch with a cadaveric donor while on the transplant waiting list~Exclusion Criteria:~* received IVIG within 6 months prior to enrollment~* HIV positive~* Positive Hepatitis Be-antigen and/or hepatitis B viral DNA~* Selective IgA deficiency or known antibodies to IgA~* Allergy to human immune globulin~* Pregnant or breast feeding

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 intravenous immune globulin (Type: OTHER): Intravenous immunoglobulin for: patients who do not have a living donor, have a PRA greater than 30% for 3 consecutive months, and have one positive crossmatch with a cadaveric donor while on kidney transplant waiting list
- Group 2 intravenous immune globulin (Type: OTHER): Intravenous immune globulin for patients who have living donors with positive crossmatch results.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=70 years of age or with ECOG PS of 2;~* advanced (stage IIIB or IV)non-small cell lung cancer;~* no prior systemic chemotherapy for advanced NSCLC or prior treatment with HER-axis targeted drugs.~Exclusion Criteria:~* active brain metastasis or spinal cord suppression;~* unstable systemic disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ECT/Succinylcholine: Biochemical, Serum and Cardiovascular Changes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. A male or non-pregnant female aged 18 years and older~2. American Society of Anesthesiologists physical status 1, 2, 3~3. Scheduled to undergo electroconvulsive therapy under general anesthesia~4. Have given written informed consent~Exclusion Criteria:~1. Pregnant or nursing~2. Any patient in the study investigators opinion who may not be suitable for research.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male or female subjects, who completed and converted from a satisfactory participation in the study 810P301, 810P302, 810P503 and 810P204 or discontinued early from the previous study during the maintenance phase and allowed to enroll only after consultation between the Investigator, the Medical Monitor and the Sponsor.~2. Medically healthy and with clinically normal laboratory profiles, vital signs, and electrocardiograms (ECGs).~3. Existing diagnosis of ADHD, as described by DSM-5 and confirmed by the K-SADS PL 2013 from study 810P301 or 810P302 or by the MINI-KID from study 810P503 or 810P204.~4. Currently receiving monotherapy treatment with FDA-approved ADHD medication (stimulants and non-stimulants).~5. Weight of at least 20 kg.~6. Written Informed Consent obtained from the subject's parent or legally authorized representative (LAR), and written Informed Assent obtained from the subject if appropriate.~Exclusion Criteria:~1. Body Mass Index (BMI) in 99th percentile or above.~2. Clinically significant change in health status, safety concern or any other reason that, in the opinion of the Sponsor or the Investigator, would prevent the subject from participating in this study or successfully completing this study.~3. Pregnancy or refusal to practice contraception during the study (for female subjects of childbearing potential and sexually active males).~4. Current substance or alcohol use.~5. Suicidal thoughts or behaviors confirmed at Visit 7 for 810P301 or 810P302, Visit 8 for 810P503 or Visit 6 for 810P204 studies.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Open-label treatment with SPN-810 (Type: EXPERIMENTAL): Subjects aged 6-17 years were treated with SPN-810 starting on day 1 with 18 mg/day. The clinician was able to adjust the dose of SPN-810 throughout the study based on subject's response and tolerability within the limits of 6 mg/day and 36 mg/day or, up to 54 mg/day for subjects with a body weight ≥ 30 kg.~The subjects were given a choice of extending their participation in the study every 6-month period for up to 36 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trigger Time in Advanced Maternal Age Patients With Low AMH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • POR defined according to the Bologna criteria:~  * AMA: ≥40 years and AMH \<1.1 ng/ml~ * Previous poor ovarian response with maximum 3 cumulus oocyte complexes retrieved after conventional stimulation~ * Antral follicle count \< 5-7~    * Cycling patients~   * Fresh ejaculates~   * ICSI~   * BMI 19-32 kg/m2~   * Ovarian stimulation protocol: Antagonist HMG 450 IU to ensure all receptors are covered and to ensure maximum recruitment. Dose adjustments can be made after 5 days of stimulation~   * Type of trigger for final oocyte maturation: dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca~   * Couples requesting preimplantation genetic testing (for aneuploidies) of their embryos~   * Follicular measurements should be performed at IVI RMA Fertility, Abu Dhabi, UAE: a single operator will perform the ultrasound for the final measurement before trigger. Recruitment can be done by all physicians~   * Only patients with an oral contraceptive pill (OCP) pretreatment to synchronize follicular development:~ * 2 weeks OCP followed by~ * a wash out of 5 days (without OCP) followed by~    * o start stimulation~   * Basal hormone profile (FSH, LH, E2, P4) measured between day 1-3 at IVIRMA Fertility, Abu Dhabi, UAE~ * FSH \<15 IU~ * E2 \<50 pg/ml~ * P \<1ng/ml~    * Only the Arab population~   * Oocyte retrieval: 36 hours after trigger~   * PGT-A~Exclusion Criteria:~* If follicular measurement before randomization shows a leading follicle ≥ 13mm~* IVF~* History of:~  * Endometriosis AFS\>2~ * Chemotherapy/radiotherapy~ * Ovarian surgery (iatrogenic)~ * Cyst puncture in the last three months~* Sonographic finding of:~  * Hydrosalpinx~ * Ovarian cyst~* Testicular samples and frozen ejaculates~* If patients are pre-screened at the start of stimulation but no follicular development is observed, patients will not be randomized~* Asynchronized follicular development at the moment of randomization: if the leading follicle is \>3 mm lager than the smaller follicles.~* All other hormonal pretreatments (except OCP) and all patients without hormonal pretreatment

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 48 Years
- Healthy Volunteers: t

Study Arms:
- Late trigger (Type: ACTIVE_COMPARATOR): dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 17 mm
- Early trigger (Type: EXPERIMENTAL): dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 14 mm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Netflix Streaming Services in the Operating Room During Total Knee Replacement - a Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. undergoing a primary elective total knee replacement by one of the orthopedic joint surgeons at Virginia Commonwealth University Medical Center~2. 18 years of age or older~3. eligible for spinal anesthesia~4. mentally capable of understanding instructions on how to request anesthesia medication~Exclusion Criteria:~1. identified as a member of regulated vulnerable population~2. ineligibility for spinal anesthesia~3. morbid obesity (body mass index greater than 40)~4. allergy to propofol or midazolam~5. pre-operative daily opioid consumption of more than 10 mg oxycodone every 6 hours (over 60 morphine miligram equivalents per day)~6. daily benzodiazepine consumption~7. history of alcohol or recreational drug abuse~8. hearing or visually impaired individuals

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Virtual Reality (Type: EXPERIMENTAL): Wear VR glasses and watch movies during surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lending a Hand to Our Future: PTSD in Refugee Children and Youth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All referrals, to the school-based health centers (SBHC) at Parkdale and Sprucecourt schools, through the school support team (SST), individual teachers, parents or community contacts.~* SBHC children and youth between the ages of 7 and 16 years of age~* All referrals to Covenant House for youth between 16 and 18 years of age (up to 19th birthday)~* Assessed to qualify for either Refugee status or Immigrant status, and who request participation and consent to research procedures~* Participants with a score of 15 or higher on UCLA PTSD-RI and are case identified (diagnosed) by paediatricians for PTSD~Exclusion Criteria:~* Participants with a score on the UCLA-PTSD-RI lower than 15.~* Participants with a score on the UCLA-PTSD-RI higher than 15 and diagnosed with PTSD by paediatrician~* Participants identified as native born~* Participants with known (previously identified) disorders that impact on communication and/or cognition, such as Developmental Disability, Autism, Communication Disability.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- NET TX (Type: EXPERIMENTAL): Behavioral intervention for PTSD (NET/KIDNET) with 8-12 sessions administered on a weekly basis.
- Delayed TX (Type: ACTIVE_COMPARATOR): Behavioral intervention for PTSD (NET/KIDNET) with 8-12 sessions administered on a weekly basis, started following a three-month wait period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* BMI 18-30 Non-smoker for at least 4 weeks~Exclusion Criteria:~* Any clinically relevant acute or chronic disease~* History of substance abuse Hypersensitivity to ketamine

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- AZD6765 75 mg (Type: EXPERIMENTAL): None
- AZD6765 150 mg (Type: EXPERIMENTAL): None
- Ketamine 0.5 mg/kg (Type: ACTIVE_COMPARATOR): None
- 125 mL sterile NaCl 0.9% (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Managed Ventricular Pacing (MVP) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Conventional indication for ICD therapy according to current evidence-based guidelines and in accordance with the corresponding United States Centers for Medicare and Medicaid Services National Coverage Determination for the use of ICDs.~* Prior myocardial infarction (MI) and an left ventricular ejection fraction (LVEF) of less than 30%~* Ischemic Dilated Cardiomyopathy (IDCM), New York Heart Association (NYHA) Class II or II heart failure, and LVEF less than or equal to 35%~* Non-Ischemic Dilated Cardiomyopathy (NIDCM) greater than 3 months, NYHA Class II or II heart failure, and LVEF less than or equal to 35%~* First ICD implant~* Successful implant with a study device with approved labeling~Exclusion Criteria:~* Failure to meet any of the inclusion criteria~* Class I pacing indication~* Chronic atrial fibrillation (AF) without any documented sinus mechanism for at least 6 months~* Inability or unwillingness to give informed consent~* Life expectancy less than 12 months or a heart transplant anticipated within 6 months~* Inability to successfully comply with study participation and follow up requirements~* Patient involved in another clinical trial that may confound the results of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VVI 40 pacing (Type: ACTIVE_COMPARATOR): Backup ventricular pacing (VVI) at 40 beats per minute
- MVP pacing (Type: ACTIVE_COMPARATOR): Managed ventricular pacing (MVP) at 60 beats per minute

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy